Key Points
- Kymera Therapeutics COO Jeremy Chadwick sold 12,905 shares on May 26 at an average price of $79.36, totaling about $1.02 million. The filing says the sale was made to cover tax withholding obligations tied to vested equity awards.
- The stock was trading modestly higher, opening at $81.70 and up about 1.2% in the session mentioned. Kymera’s shares have traded between a 52-week low of $28.33 and a high of $103.00.
- Wall Street remains largely bullish on KYMR, with an average analyst rating of “Moderate Buy” and a target price of $118.10. Recent earnings also beat expectations, with revenue of $34.37 million topping forecasts and EPS coming in better than expected.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 4,279 shares of the business's stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $81.58, for a total transaction of $349,080.82. Following the completion of the sale, the chief operating officer directly owned 44,018 shares of the company's stock, valued at $3,590,988.44. The trade was a 8.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kymera Therapeutics Stock Performance
KYMR opened at $81.70 on Thursday. The company has a 50-day moving average of $83.28 and a 200-day moving average of $79.14. The company has a market capitalization of $6.72 billion, a P/E ratio of -22.89 and a beta of 2.06. Kymera Therapeutics, Inc. has a 1-year low of $28.33 and a 1-year high of $103.00.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company's revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.82) EPS. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
KYMR has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They issued a "buy" rating and a $110.00 target price for the company. Morgan Stanley reissued an "overweight" rating and set a $119.00 target price on shares of Kymera Therapeutics in a report on Thursday, April 30th. Citigroup increased their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $118.10.
View Our Latest Stock Analysis on Kymera Therapeutics
Institutional Investors Weigh In On Kymera Therapeutics
A number of hedge funds have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP lifted its stake in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock valued at $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock valued at $581,610,000 after buying an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock valued at $479,258,000 after buying an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. lifted its stake in Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock valued at $487,685,000 after buying an additional 845,922 shares during the last quarter. Finally, Holocene Advisors LP bought a new stake in Kymera Therapeutics in the third quarter valued at $47,563,000.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
